Acumen Pharmaceuticals Analyst Price Targets - Benzinga

Acumen Pharmaceuticals Inc

ABOSNASDAQ

Trade with Public

Trade with Public

$1.98

-0.08-3.88%

마지막 업데이트: Oct 23, 9:25 AM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 비교 옵션 주식 보고서

© 2026 Benzinga | All Rights Reserved

Acumen Pharmaceuticals Analyst Price Targets - Benzinga

Acumen Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Acumen Pharmaceuticals (ABOS).

Price Target Range — 11 Quarters

Analyst Consensus — 6 Analysts

6Buy

Consensus RatingBuy# Analysts6Avg. Consensus PT$7Upside to Avg. PT+247.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 16, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Sep 15, 2026	Citigroup	Geoff Meacham	PT Raise	Buy	$4→$5
Mar 26, 2026	BTIG	Thomas Shrader	Maintained	Buy	$8
Mar 16, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$7→$8
Jan 27, 2026	BTIG	Thomas Shrader	PT Raise	Buy	$4→$7
Nov 18, 2025	B of A Securities	Geoff Meacham	PT Cut	Buy	$9→$8
Aug 25, 2025	B of A Securities	Geoff Meacham	PT Cut	Buy	$10→$9
Jun 17, 2025	Citigroup	Geoff Meacham	Initiate	Buy	$4
Mar 28, 2025	UBS	Colin Bristow	PT Cut	Buy	$6→$4
Mar 28, 2025	HC Wainwright & Co.	Andrew Fein	PT Cut	Buy	$15→$11
Nov 13, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Oct 3, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Aug 15, 2024	UBS	Colin Bristow	PT Cut	Buy	$14→$6
Aug 14, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Jul 25, 2024	Citigroup	David Hoang	Initiate	Buy	$7
May 15, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Mar 31, 2024	UBS	Colin Bristow	PT Cut	Buy	$15→$14
Mar 27, 2024	HC Wainwright & Co.	Andrew Fein	Maintained	Buy	$15
Dec 12, 2023	Deutsche Bank	Neena Bitritto-Garg	Initiate	Buy	$8

Analyst Ratings News

PRO
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target

BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.

Benzinga Newsdesk

Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7

BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.

Benzinga Newsdesk

PRO
B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9

B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $10 to $9.

Benzinga Newsdesk